In September, Bitdeer produced 1,355 Bitcoin (BTC) with a self-mining hashrate of 82.3 EH/s and co-mining at 28.7 EH/s, supported by an AI Cloud revenue backlog of about $2.9 billion. Meanwhile, TeraWulf's BTC production dropped to 347 in the first half of 2026 from 857 in the same period of 2025, as it repurposed two mining buildings for high-performance computing (HPC) at its Lake Mariner campus, which has 145 MW of Bitcoin mining and 81 MW of HPC capacity. This shift reflects TeraWulf's strategic move to diversify its operations beyond mining. The production figures cover different periods: Bitdeer's September output and TeraWulf's first half of 2026.
Bitdeer’s Bitcoin mining output and AI backlog provide context for digital asset trends. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 26, 2026 18:21 WIB: 26 of 50 major cryptocurrencies rose, 23 fell. CAKE rose 2.56% to Rp38.321 with 94% sell orders; BCH rose 2.45% to Rp5.026.753 with 81% sell orders; THETA fell 2.36% to Rp3.271 with 87% buy orders.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
